Pfizer says its booster shot is 95.6% effective against symptomatic Covid

Regulators have wrestled with how widely to use boosters as the fast-spreading delta variant drives infection rates up

Naomi Kresge | Bloomberg
Pfizer Vaccine, Coronavirus vaccine

The trial results show that “booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy,” BioNTech CEO Ugur Sahin said.

Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely.
A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said on Thursday. 
Pfizer shares were 0.9% higher in premarket U.S. trading, with BioNTech gaining 1.3% in Frankfurt.

Also Read

UK to roll out Covid-19 booster jabs for over-50s from next week

Vulnerable people can get Covid-19 vaccine booster shot: WHO Europe

US plans Covid-19 booster shots at six months instead of eight: Report

Covid protection wanes months after second shot, booster needed: Studies

Covid-19 pandemic: EU panel backs booster shots of Pfizer, Moderna

Rs 25 Cr be disbursed for kids who lost parents to Covid-19 in Maha: SC

Gujarat vaccinates 90% of eligible population with first dose of Covid vax

Healthcare industry leaders hail 100-crore Covid-19 vaccination milestone

WHO chief congratulates PM, health workers as India hits vaccine milestone

India registers over 18,000 new Covid-19 infections, 160 more fatalities

First Published: Oct 21 2021 | 4:59 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to